ClinicalTrials.gg
RecruitingNCT05364749Can-SCAHnUpdated Apr 14, 2026

Selective CT for Anticoagulated Head Injured Patients

An observational study in Head Injury, Traumatic Brain Injury and Intracranial Hemorrhage, Traumatic, sponsored by Dr. Kerstin de Wit. Recruiting at 7 sites in Canada. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Primary conditionBrain Injuries, TraumaticRegistry: Craniocerebral TraumaReclassifiedWhy we changed it
Registry
Craniocerebral Trauma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Brain Injuries, Traumatic
Why
  1. The study's listed conditions name Brain Injuries, Traumatic, a narrower term within Craniocerebral Trauma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Dr. Kerstin de Wit · Observational

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,000
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Brain Injuries, Traumatic with a site in Canada — 20 open to participants now, 22 under way, 2 of them phase 3. Brain Injuries, Traumatic · Canada.

Planned enrollment
Largest of 18
4,000 · median 135
Started
2022
with 1 other
Observational
18 of 69
8 open now
Primary completion
2026-03
later than 5 of 21 live
Registered
58th of 69
by date

Among the 69 studies in Brain Injuries, Traumatic with a site in Canada, this one has the largest planned enrollment of the 18 observational ones that give a count, is one of 2 that started in 2022, is one of 18 observational ones, reaches primary completion later than 5 of the 21 other live ones, and was the 58th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

20 of the 69 studies in Brain Injuries, Traumatic with a site in Canada are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 16 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Brain Injuries, Traumatic with a site in Canada, or all of them as a file.
02

Study summary

The goal is to derive and a clinical decision rule for safe exclusion of traumatic brain injury without neuroimaging in head-injured ED patients who take anticoagulant medications.

The objectives are to:

  1. Derive and externally validate a new highly sensitive and maximally specific clinical decision rule for the exclusion of traumatic brain injury in head-injured ED patients who take anticoagulant medications; and,
  2. Estimate the sensitivity and specificity of existing head injury clinical decision rules in head-injured ED patients who take anticoagulant medications.
Read the detailed description

This is a prospective cohort study enrolling 4000 anticoagulated patients presenting with blunt head trauma to the emergency department. Emergency physicians will record the presence or absence of clinical predictors for traumatic brain injury at the time of assessment. All patients will undergo head CT scanning and are followed for 30 days.

The adjudicated primary outcome is clinically important traumatic brain injury diagnosed at the index ED presentation. The secondary outcome is delayed clinically important traumatic brain injury, diagnosed within 30 days of normal index head CT scan.

The primary analysis will be to derive a novel clinical decision rule which excludes clinically important traumatic brain injury diagnosed at the index ED visit. The secondary analyses will include:

  1. The diagnostic accuracy of existing head injury clinical decision rules in diagnosing clinically important traumatic brain injury on index ED visit, in patients who take anticoagulation; and,
  2. The sensitivity and specificity of the new and existing rules for the diagnosis of both index and delayed clinically important traumatic brain injury.
03

Conditions studied

  • Head Injury
  • Traumatic Brain Injury
  • Intracranial Hemorrhage, Traumatic
  • Blunt Head Injury

Browse trials for

04

In context

Brain Injuries, Traumatic Reclassified

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

This study's planned enrollment of 4,000 is above the median of 116 across 558 observational studies indexed under Brain Injuries, Traumatic.

Browse Brain Injuries, Traumatic studies →

Lead sponsor

Dr. Kerstin de Wit is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Compared within Brain Injuries, Traumatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Craniocerebral Trauma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study enrolls a anticoagulated emergency department patients presenting within 48 hours of a blunt head injury.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥16 years
  • Presents to the emergency department after a head injury
  • Patient has a head CT in the emergency department
  • Is a current anticoagulant user

Exclusion criteria

Exclusion Criteria:

  • Head injury occurred >48 h before patient's arrival to the emergency department
  • Penetrating head injury
  • Previously enrolled
  • Patient resides outside of the hospital's catchment area
  • Patient was transferred from another emergency department following neuroimaging
  • Patient was not managed by the emergency or trauma physician in the emergency department
  • Leaves the emergency department prior to completion of their medical assessment
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,000 participants (estimated)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. Clinically important traumatic brain injury

    Clinically important TBI is defined as the diagnosis of bleeding within the cranial vault, diffuse axonal injury or an isolated skull fracture, which also receives hospital intervention or causes death within 90 days of the traumatic brain injury diagnosis.

    Time frame: Index emergency department presentation

Secondary outcomes

  1. Delayed clinically important traumatic brain injury

    Clinically important TBI is defined as the diagnosis of bleeding within the cranial vault, diffuse axonal injury or an isolated skull fracture, which also receives hospital intervention or causes death within 90 days of the traumatic brain injury diagnosis.

    Time frame: Diagnosed within 30 days of a negative index head CT scan at the index emergency department presentation

08

Study locations

1 of 7 sites recruiting
  • University of British Columbia
    Vancouver, British Columbia V6T 1Z4, Canada
    Not yet recruiting
    • David Barbic, MD · Contact
    • David Barbic, MD · Principal investigator
  • Hamilton Health Sciences Corporation
    Hamilton, Ontario L8L 2X2, Canada
    Not yet recruiting
    • Natasha S Clayton, CRA, RA · Contactclaytonn@hhsc.ca
    • Alim Pardhan, MD · Principal investigator
  • Kingston Health Sciences Centre
    Kingston, Ontario N3T 6P9, Canada
    Recruiting
  • Ottawa Hospital Research Institute
    Ottawa, Ontario K1H 8L6, Canada
    Not yet recruiting
    • Gabriel Sandino-Gold · Contact
    • Debra Eagles, MD · Principal investigator
  • Sinai Health
    Toronto, Ontario M5G 1X5, Canada
    Not yet recruiting
    • Shelley McLeod, PhD, MSc · Contact
    • Catherine Varner, MD · Principal investigator
  • Hôpital du Sacré-Cœur de Montréal
    Montreal, Quebec H4J 1C5, Canada
    Not yet recruiting
    • Chantal Lanthier, RN · Contact
    • Justine Lessard, MD · Principal investigator
  • CHU de Québec - Université Laval
    Québec, Quebec G1R 2J6, Canada
    Not yet recruiting
    • Alexandra Nadeau · Contact
    • Éric Mercier, MD · Principal investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Mar 2026, 49 months.

Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's 49 months is close to that.

Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2022
First posted
May 6, 2022
StartActual
Feb 1, 2022
Primary completionActual
Mar 15, 2026
CompletionEst.
Sep 30, 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05364749
Lead sponsor
Dr. Kerstin de Wit
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Dr. Kerstin de Wit (Associate Professor, Queen's University) — Sponsor-investigator
First posted
May 6, 2022
Start date
Feb 1, 2022
Primary completion
Mar 15, 2026
Completion
Sep 30, 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Natasha Clayton, CRA, RA
Contact
natasha.clayton@queensu.ca
416-566-3590
Kerstin de Wit, MD
principal investigator · Queens University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion